The race to be first to market with a COVID-19 vaccine is changing gears. As the companies developing vaccine/therapeutics move further down the development path, the commercial aspect is starting to take a more prominent part in the conversation.mRNA vaccine maker Moderna (MRNA) is one of the companies currently leading the pack, but it needs to be vigilant of rivals’ progress. Shares of Moderna hit a speed bump on Wednesday and trended downwards on account of positive developments in the progress of rivals Novavax (NVAX) and Johnson & Johnson’s (JNJ) respective COVID-19 vaccine programs.Novavax’ candidate NVX-CoV2373 performed well in a …read more
Source:: Yahoo Finance
